Business Insider

Start of bridging pharmacokinetic and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator O304

Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304 STOCKHOLM, Aug. 17, 2020 ...
Business Wire

Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH

The primary objective of the study was to assess the full pharmacokinetic (PK) profile of PXL770 as well as to evaluate safety and tolerability. PXL770 is a first-in-class direct adenosine ...
Business Wire

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 ...
Business Insider

China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program

STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Balticgruppen Bio, the Umea based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a ...